Sparks - SynAct Pharma

SynAct Pharma has initiated patient dosing in the Phase II RESOVIR-2 study evaluating resomelagon as an add-on therapy targeting dengue-associated hyperinflammation, representing a further step in extending its host-directed, inflammation-resolution strategy into acute infectious settings (following the Phase II RESPIRE study initiation in viral respiratory insufficiency in January 2026). The study is a randomised, placebo-controlled trial (n=120; 1:1) assessing time to disease resolution and progression to severe dengue, with top-line data anticipated in Q326.

While resomelagon’s investment case remains anchored to the Phase IIb ADVANCE readout in rheumatoid arthritis (expected by mid-2026), we view RESOVIR-2 as a strategically relevant programme that broadens the therapeutic scope of its melanocortin-driven mechanism. The study builds on prior COVID-19 proof-of-concept data and offers incremental optionality in the medium term.